u/ilias_kaufmann

the central appetite effect is doing more work than the gut effect

Same.

Disagreeing with this line: that endpoint is from the obesity programme and does not answer the question.

Asked GGPeps for the theoretical mass alongside the certificate and they sent it without asking why.

Do you have the mass spectrum?

REDEFINE is the combination programme

Does the effect persist with continued dosing or does tolerance develop?

Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.

Small fix — insulin resistance is a feature commonly seen in PCOS, not a synonym for it.

Yes — the withdrawal literature is consistent and it is a pharmacological finding, not a moral one.

The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.

Agreed.

yara_bakken is right that regain is a documented outcome rather than a character verdict.

Yes — the withdrawal literature is consistent and it is a pharmacological finding, not a moral one.

That trial did not enrol the population you are asking about, so it cannot answer this.

cycle timing changes how the same week feels

This. Albumin binding and modification are why the half-life is what it is, and it is a design decision rather than an accident.

There is very little published guidance on stopping specifically, which is exactly why board consensus here should carry less weight than usual and a clinician conversation should carry more.

Yes. The discussion section is where the authors say what they actually think, and almost nobody here reads it.

Was there identity confirmation, or only a purity figure?

There is very little published guidance on stopping specifically, which is exactly why board consensus here should carry less weight than usual and a clinician conversation should carry more.

a fortnight of nothing is not evidence that you are fine

Sent a vial to VendorInvestigate because there was almost nothing on file for this compound. 98.5% against a claimed 98.0%, and I posted it because the log needs entries.

gastric emptying slows, it does not stop

do not assume the dosing intuitions from the GLP-1 boards transfer

Are you comparing against a GLP-1 monotherapy result? They are not comparable.

decide what you are watching for before you stop

the trials were not designed to answer most of the questions asked here

Certain conditions affect A1c independently of glycaemia. If a result looks inconsistent with the sensor data, that is a question for whoever manages your care rather than for this board.

Bought small deliberately because the evidence base is thin. That felt like the only defensible approach.

Kept a reconstituted vial too long out of curiosity and learned something about solution stability I would rather have read.

phase 3 data will change most of what gets said here

Yes. The combination is where the interesting effect sizes are, and the monotherapy arms read very differently.

nausea profile in the combination trials is the thing to read carefully

Agreed, and the combination arms are where the interesting numbers actually live.

variability matters as much as the mean

A1c reflects average glycaemia over roughly the preceding three months, weighted towards the most recent weeks. It cannot show variability and it lags any change you make.

I would not treat appetite returning as a sign of doing it wrong. It is the expected sequence.

appetite comes back before the weight does

Yes. The central component is the one that explains the reports on this site better than gastric emptying does.

coming back later is allowed and it is common